Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Neonatal but not juvenile gene therapy reduces seizures and prolongs lifespan in SCN1B–Dravet syndrome mice
Chunling Chen, … , David R. Hampson, Lori L. Isom
Chunling Chen, … , David R. Hampson, Lori L. Isom
Published January 23, 2025
Citation Information: J Clin Invest. 2025;135(5):e182584. https://doi.org/10.1172/JCI182584.
View: Text | PDF
Research Article Neuroscience Article has an altmetric score of 88

Neonatal but not juvenile gene therapy reduces seizures and prolongs lifespan in SCN1B–Dravet syndrome mice

  • Text
  • PDF
Abstract

Dravet syndrome (DS) is a developmental and epileptic encephalopathy (DEE) that begins in the first year of life. While most cases of DS are caused by variants in SCN1A, variants in SCN1B, encoding voltage-gated sodium channel β1 subunits, are also linked to DS or to the more severe early infantile DEE. Both disorders fall under the OMIM term DEE52. Scn1b-null mice model DEE52, with spontaneous generalized seizures and death in 100% of animals in the third postnatal week. Scn1b-null cortical parvalbumin-positive interneurons and pyramidal neurons are hypoexcitable. The goal of this study was to develop a proof-of-principle gene replacement strategy for DEE52. We tested an adeno-associated viral vector encoding β1 subunit cDNA (AAV-Navβ1) in Scn1b-null mice. We demonstrated that AAV-Navβ1 drives β1 protein expression in excitatory and inhibitory neurons in mouse brains. Bilateral intracerebroventricular administration of AAV-Navβ1 in Scn1b-null mice at postnatal day 2 (P2), but not at P10, reduced spontaneous seizure severity and duration, prolonged lifespan, prevented hyperthermia-induced seizures, and restored cortical neuron excitability. AAV-Navβ1 administration to WT mice resulted in β1 overexpression in brain but no obvious adverse effects. This work lays the foundation for future development of a gene therapeutic strategy for patients with SCN1B-linked DEE.

Authors

Chunling Chen, Yukun Yuan, Heather A. O’Malley, Robert Duba-Kiss, Yan Chen, Karl Habig, Yosuke Niibori, Samantha L. Hodges, David R. Hampson, Lori L. Isom

×

Figure 3

AAV-Navβ1 restores Scn1b-null PV+ interneuron excitability.

Options: View larger image (or click on image) Download as PowerPoint
AAV-Navβ1 restores Scn1b-null PV+ interneuron excitability.
(A) Represen...
(A) Representative traces showing evoked repetitive firing of untreated PV+ interneurons in cortical layer 2/3 brain slices from P16–18 WT (black) or null (blue) mice. Repetitive AP firing was evoked by injections of 1,500-millisecond currents from –60 pA to 330 pA at 10-pA steps from RMP. A representative null interneuron began to fire APs at lower intensities of current injection compared with the WT. Stronger depolarizing current injections blocked repetitive firing in the null interneuron. (B) Representative traces showing evoked repetitive firing of cortical layer 2/3 PV+ interneurons in slices from P16–18 WT (orange) or null (green) mice following a single dose of AAV-Navβ1 at P2. WT and null interneurons showed similar AP firing patterns in response to current injections. (C) I-O curves for AP firing of untreated WT (black) versus null (blue) PV+ interneurons in response to current injections. I-O curves were generated by plotting of the number of APs evoked by 1,500-millisecond current injections against current intensities over a range of –60 pA to 330 pA. Asterisks denote significant differences between genotypes (P < 0.05). (D) I-O curves for AP firing of WT (orange) versus null (green) PV+ interneurons following AAV-Navβ1 treatment. Values are mean ± SEM of 13 cells from 7 untreated WT mice, 17 cells from 6 AAV-treated WT mice, 18 cells from 7 untreated null mice, or 12 cells from 6 AAV-treated null mice. No significant differences between genotypes. (E) tdTomato-labeled PV+ neurons (cyan) in P17 somatosensory cortex of AAV-treated Scn1b–/–/PV-Cre/tdTomato mice show variable expression of AAV-Navβ1 (magenta) among PV+ neurons. Arrows, myc antibody labeling (left) in PV+ neurons (middle) with merged image (right). Scale bar: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 9 news outlets
Blogged by 4
Posted by 11 X users
Referenced by 1 Bluesky users
5 readers on Mendeley
See more details